In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Myocardial fibrosis is reflected by two novel biomarkers of collagen formation in patients with cirrhosis: results from a prospective study with advanced cardiac MRI

Session Poster Session 5

Speaker Alexander Lynge Reese-Petersen

Event : ESC Congress 2018

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Biomarkers
  • Session type : Poster Session

Authors : AL Reese-Petersen (Herlev,DK), S Wiese (Hvidovre,DK), S Moeller (Hvidovre,DK), S Genovese (Herlev,DK)

Authors:
A.L. Reese-Petersen1 , S. Wiese2 , S. Moeller2 , S. Genovese1 , 1Nordic Bioscience, Cardiovascular Fibrosis - Herlev - Denmark , 2Hvidovre Hospital - Copenhagen University Hospital, Department of Clinical Physiology and Nuclear Medicine - Hvidovre - Denmark ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 995

Background and aims: Cardiac dysfunction is often seen in patients with advanced cirrhosis. Diffuse myocardial fibrosis (DMF) seems to play an important role in the underlying pathophysiology of cirrhotic cardiomyopathy. Thus, the myocardial extracellular volume (ECV), which reflects the degree of myocardial fibrosis as assessed by cardiac MRI seems to be increased in cirrhosis and associated with liver and cardiac dysfunction. Upregulation of collagen production and deposition in the heart is the main feature of DMF. Elevated biomarkers of collagen formation indicate an ongoing process of fibrogenesis. PRO-C3 has previously proven to be a marker of hepatic fibrosis in patients with different liver diseases and PRO-C6 has been associated with adverse outcomes in kidney failure. Our aim was therefore to evaluate the association between presence of DMF as assessed by cardiac MRI with ECV quantification and circulating levels of two novel biomarkers of collagen type III and type VI formation.

Methods: Sixty-three stable cirrhotic patients underwent a cardiac MRI with ECV quantification, ECG including QTc interval, clinical and biochemical assessments. Formation of collagen type III and type VI was assessed in serum by means of enzyme-linked immunosorbent assays (PRO-C3 and PRO-C6, respectively), measuring the concentration of the pro-peptides of the two collagens, which are cleaved and released in circulation during maturation of newly synthesized collagen molecules.

Results: PRO-C3 and PRO-C6 were increased in serum of the investigated patients in comparison to the assay normal range (mean (2.5–97.5 percentile) PRO-C3: 54.3 (11.2–147.2) vs. 12.1 (6.7–22.2) ng/ml, p<0.0001 and mean (2.5–97.5 percentile) PRO-C6: 14.5 (5.1–34.7) vs. 8.0 (4.9–12.2) ng/ml, p<0.0001). Moreover, there was a positive correlation of both markers to ECV (PRO-C3: r=0.33 p=0.016; PRO-C6: r=0.39 p=0.005) and QTc (PRO-C3: r=0.314, p=0.016; PRO-C6: r=0.343, p=0.008). When dividing the patients in two groups according to the median myocardial ECV level (31%), levels of both markers were significantly more elevated in patients in the high ECV group (PRO-C3 p=0.031; PRO-C6 p=0.003).

Conclusion: In stable cirrhotic patients, PRO-C3 and PRO-C6 are associated with increased myocardial ECV, which reflects DMF. In addition, the association of the biomarkers to the prolonged QTc interval suggests that increased cardiac fibrosis is involved in the electrophysiological abnormalities in cirrhosis. The novel biomarkers of collagen formation may therefore be valuable in the investigation of presence and pathophysiology of cardiac dysfunction in cirrhosis.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are